Details for Patent: 7,612,058

Which drugs does patent 7,612,058 protect, and when does it expire?

Patent 7,612,058 protects ZETIA and is included in one NDA.

Protection for ZETIA has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has two hundred and thirty-five patent family members in thirty-eight countries.

Summary for Patent: 7,612,058

Title:	Methods for inhibiting sterol absorption
Abstract:	The present invention provides compositions, therapeutic combinations and methods including: (a) at least one peroxisome proliferator-activated receptor activator; and (b) at least one substituted azetidinone or substituted .beta.-lactam sterol absorption inhibitor which can be useful for treating vascular conditions, diabetes, obesity and lowering plasma levels of sterols.
Inventor(s):	Cho; Wing-Kee Philip (Princeton, NJ)
Assignee:	Schering Corporation (Kenilworth, NJ)
Application Number:	10/998,400
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 7,612,058
Patent Claim Types: see list of patent claims	Use; Composition; Compound;

Drugs Protected by US Patent 7,612,058

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Organon	ZETIA	ezetimibe	TABLET;ORAL	021445-001	Oct 25, 2002	AB	RX	Yes	Yes					Y

International Family Members for US Patent 7,612,058

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	032403
Argentina	032643
Argentina	033855
Argentina	034204